What is the preferred choice between rifampicin and rifabutin (anti-tubercular drugs) for a patient with tubercular pericarditis, considering potential interactions with antiretroviral therapy in HIV-positive patients?

Rifampicin vs Rifabutin for Tubercular Pericarditis

Direct Recommendation

For tubercular pericarditis in HIV-negative patients or those not on antiretroviral therapy, use rifampicin-based regimens (isoniazid, rifampicin, pyrazinamide, and ethambutol for 2 months, followed by isoniazid and rifampicin for 4 months). 1 For HIV-positive patients on protease inhibitors or NNRTIs (except efavirenz with specific regimens), substitute rifabutin for rifampicin with appropriate dose adjustments. 2

---

Treatment Algorithm Based on HIV and ART Status

HIV-Negative or Not on ART

• Use standard rifampicin-based 6-month regimen: isoniazid, rifampicin, pyrazinamide, and ethambutol for 2 months, then isoniazid and rifampicin for 4 months 1
• Rifampicin is preferred because it has been validated in approximately 90 controlled clinical trials demonstrating superior efficacy, faster bacteriologic response, and shorter treatment duration (6 months vs 12-15 months for non-rifamycin regimens) 2
• Regimens excluding rifamycins have higher rates of treatment failure, death, and increased transmission risk 2

HIV-Positive on Efavirenz-Based ART

• Rifampicin can be used without dose adjustment when combined with efavirenz 600 mg daily plus two NRTIs 2, 3
• This is a preferred first-line option for TB-HIV co-infection 4

HIV-Positive on Dolutegravir-Based ART

• Rifampicin can be used, but dolutegravir must be increased to 50 mg twice daily (not once daily) 3
• Combine with tenofovir/emtricitabine or lamivudine as NRTI backbone 3

HIV-Positive on Protease Inhibitors

• Rifampicin is contraindicated with all protease inhibitors except ritonavir-boosted regimens 2
• Use rifabutin instead with the following dose modifications 2:
  • Initial phase: rifabutin 150 mg daily (or 300 mg twice weekly after 2-4 weeks) with isoniazid, pyrazinamide, and ethambutol for 8 weeks 2
  • Continuation phase: rifabutin 300 mg twice weekly with isoniazid for 4 months to complete 6 months total 2
  • When combined with ritonavir (with or without other protease inhibitors): reduce rifabutin to 150 mg two or three times per week 2
  • When combined with saquinavir soft-gel capsule plus NRTIs: use standard rifabutin dose (300 mg daily or twice weekly) 2

HIV-Positive on Other NNRTIs

• Delavirdine: rifabutin is contraindicated 5
• Nevirapine: rifabutin can be used with dose adjustments 2
• Rilpivirine, doravirine, bictegravir: co-administration with rifabutin is not recommended due to significant drug level reductions 5

---

Critical Pharmacologic Considerations

Why Rifampicin is Preferred When Possible

• Rifabutin may be more reliably absorbed than rifampicin in patients with advanced HIV disease 2
• Rifabutin appears better tolerated in patients with rifampicin-induced hepatotoxicity 2
• Rifabutin has fewer interactions with azole antifungals, anticonvulsants, and methadone 2
• However, clinical data from approximately 30 HIV-infected patients showed 80% sputum conversion by 2 months with rifabutin regimens, with minimal adverse reactions (one case of uveitis) and no TB relapses at 1-year follow-up 2

Mechanism of Drug Interactions

• Rifampicin is a potent inducer of cytochrome P450 enzymes, markedly lowering protease inhibitor and NNRTI blood levels, resulting in suboptimal antiretroviral therapy 2, 4
• Rifabutin is a less potent CYP450 inducer, allowing concurrent use with most protease inhibitors when doses are appropriately modified 2, 4
• Rifampicin's enzyme induction persists for at least 2 weeks after discontinuation 2

---

Common Pitfalls and How to Avoid Them

Timing of ART Initiation

• For patients not yet on ART, consider staggered initiation: start TB treatment first, then add ART at the end of the 2-month intensive phase or after TB treatment completion 2
• This approach promotes adherence and reduces combined drug toxicity 2
• Monitor HIV viral load and CD4+ counts every 3 months during TB treatment to guide ART initiation timing 2

Rifabutin-Specific Adverse Events

• Monitor for uveitis, especially when rifabutin is combined with clarithromycin or fluconazole 5
• Obtain periodic hematologic studies as rifabutin may cause neutropenia and thrombocytopenia 5
• Watch for severe cutaneous adverse reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS) 5

Intermittent Rifabutin Regimens

• Twice-weekly intermittent rifabutin-based regimens in HIV-infected patients with advanced disease have been associated with acquired rifamycin resistance 6
• Daily therapy during the intensive phase is preferred, with twice-weekly dosing reserved for the continuation phase 2

Alternative Non-Rifamycin Regimens

• If rifamycins cannot be used due to complex drug interactions or intolerance, a 9-month streptomycin-based regimen can be considered: isoniazid, streptomycin, pyrazinamide, and ethambutol for 2 months, then isoniazid, streptomycin, and pyrazinamide 2-3 times weekly for 7 months 2
• However, non-rifamycin regimens are suboptimal and associated with higher relapse rates (18-24% at 6 months vs 5-6% at 9 months) 2

---

Adjunctive Corticosteroid Therapy

• Evidence for corticosteroids in tuberculous pericarditis is limited 1
• One controlled trial showed prednisolone supplementation resulted in more rapid clinical improvement, lower mortality (4% vs 11%), and reduced need for pericardiectomy (21% vs 30%) 7
• However, safety in HIV-infected patients has not been conclusively established 1
• If used, prednisolone should be given for the first 11 weeks of TB treatment 7

---

Monitoring Requirements

• Directly observed therapy (DOT) should be used for all HIV-TB co-infected patients 2
• Close monitoring for TB treatment failure, antiretroviral treatment failure, paradoxical reactions, and drug toxicities is essential 2
• Management should be directed by or in consultation with a physician experienced in treating both TB and HIV 2